Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just read in the results that we received 5mil for the Excalibur deal so could quite easily be the full whack if we receive the contract
Strong revenue growth from 2.1 last year to 9.1 million this year is the financial highlight but the rest doesn’t make the best reading. You read the operational highlights and to a new investor it sounds promising I suppose small biotech and pharma companies have high cash burn and this something one has to accept. Market open will be interesting
First order didn’t go through 2.36 it is :(
What is going on with the spread on here though very strange
Just got quoted below 2 quid couldn’t believe my eyes so checked for another rns by the time I was back I was being offered 2.19 now in at 2.27. Should have went for it first time, lesson learnt
Resale is extremely popular in young people and not only does it help with the sustainable side of the business but if they apply analytics to it which I’m sure they will, They will be able to see which items are selling the best and use this to potentially decide to do re runs of heavily resold items
It surprises me that this share doesn’t get a bit more attention. I think profitability is the big IF that will hopefully be answered upon release of the results. Once we are profitable then we have the full package and I can see a move up very soon after.
What are people’s thoughts on takeover potential at this price? Surely potential interested parties catch wind of a low share price and see an opportunity?
Do you have an article saying why Thursday is the judgement day? Not in the loop with this as I’ve only read the proactive article.
Really doesn’t get much better does it? Hopefully with the drop back over the past few days some smart money will notice this is cheap. Like you say though medium to long term hold for me hearing more and more about digital clinical trials they are a great way for companies to save money. Order book looks great as well!
Lol doc I think ‘those people are all dead’ is probably a bit of an overstatement maybe those people who had underlying health issues are mostly dead and the rest are fine and have immunity for at least 180 days
You do have to wonder if the reason it takes such a long time for treatments to get trials filled and subsequent approvals data/readouts is because govs are scared it will reduce vaccine uptake and subsequently the size of their brown envelopes
I’m holding a share that’s dual listed on main market and Nasdaq atm (tils/tlsa). Generally the prices run pretty close although sometimes you find that Americans lead the way up as they seem to react to news better unless it’s dilution they don’t like that lol. Also you occasionally get a drop to in share price about 2 in the afternoon before nasdaq opens then it shoots straight back up when they open.
Looks like I could have timed my buy a bit better hopefully get an rns soon
I did think the same it is a lot of money and to sell it on an individual person basis? Surely should be going to companies rather than one doctor.
Hopefully we have a good sales team in place the other notable factor is if this does end up replacing control arms in clinical trials it’s going to save companies a hell of a lot of money and potentially save life’s of those who may have died on a placebo arm so I can definitely see the value in it however it might have been wiser to do an introductory price while the patients datasets are still growing.
Do people think we still have a block seller? The 180s feel like miles away :(
This could make us a very good amount of money if uptake is strong. Currently 2 million patient datasets expanding to 10 million by end of December. Valuable tool for researchers. Ever expanding to eventually cover all diseases is the aim sounds good to me.
Lowering the TO risk from ganfeng was my thoughts exactly. Still a bargain at this price but it’s hard to buy more when average is below 15p
Really encouraging rns, particularly like where they mention that profit expectations far exceed those at the time of the RTO.
It sounds like our products are hitting the market at exactly the right time as they say ESG market is going to grow 5x plenty of potential customers for us.
Around 4:20 in the video he literally says ‘number 1 foralumab could be used to replace this lymphodepleting chemotherapy’ granted it’s a could but it’s a nice one to think about.
To anyone who has read the rns but hasn’t bothered to listen to the interview listen to this now. Sounds extremely positive one highlight for me was the potential for foralumab to replace the chemo part of car t therapy. Could be groundbreaking